https://www.cdc.gov/csels/dls/locs/2021/07-21-2021-lab-alert-Changes_CDC_RT-PCR_SARS-CoV-2_Testing_1.html
After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.
[url=https://t.emailupdates.cdc.gov/r/?id=h4c129f9a,147a6e6f,147a9998&ACSTrackingID=USCDC_2146-DM61940&ACSTrackingLabel=Lab Alert%3A Changes to CDC RT-PCR for SARS-CoV-2 Testing]Visit the FDA website[/url] for a list of authorized COVID-19 diagnostic methods. For a summary of the performance of FDA-authorized molecular methods with an FDA reference panel, [url=https://t.emailupdates.cdc.gov/r/?id=h4c129f9a,147a6e6f,147a9999&ACSTrackingID=USCDC_2146-DM61940&ACSTrackingLabel=Lab Alert%3A Changes to CDC RT-PCR for SARS-CoV-2 Testing]visit this page[/url].